BioAge Labs, Inc. (BIOA) compared with its closest peers (RZLT, RLMD, PBYI, BNTC, AVIR). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Rezolute, Inc. (RZLT) | $490.13M | -4.5 |
| Relmada Therapeutics, Inc. (RLMD) | $487.74M | -3.3 |
| Puma Biotechnology, Inc. (PBYI) | $476.97M | 17.9 |
| Benitec Biopharma Inc. (BNTC) | $464.64M | -11.1 |
| Atea Pharmaceuticals, Inc. (AVIR) | $434.71M | -1.8 |
| Foghorn Therapeutics Inc. (FHTX) | $420.74M | -4.5 |
| Enanta Pharmaceuticals, Inc. (ENTA) | $390.28M | -2.8 |
| Rocket Pharmaceuticals, Inc. (RCKT) | $384.21M | -1.7 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $382.29M | -2.5 |
| Lyell Immunopharma, Inc. (LYEL) | $380.32M | -1.9 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
BIOA overview · BIOA earnings · BIOA financials · BIOA KPIs · BIOA investor relations · BIOA ownership · BIOA filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.